Hope Rugo

Hope S. Rugo, a leading expert in hormone receptor-positive breast cancer and Professor at UCSF, shares groundbreaking insights on the latest research. She discusses pivotal findings from the TROPiCS-02 trial, noting significant improvements in patient outcomes. The conversation highlights advancements in antibody-drug conjugates and their potential synergy with immunotherapy. Additionally, Rugo addresses the impact of ribociclib on post-progression treatments, emphasizing its advantages over traditional chemotherapy, and examines optimal dosing strategies from the AMELY trial.

Dr. Hope Rugo, a leading breast medical oncologist from City of Hope, shares her expert insights on metastatic hormone receptor-positive breast cancer, highlighting key findings from the SABCS 2025 conference. She discusses the superiority of CDK4-6 inhibitors over chemotherapy, strategies for choosing effective treatments, and the significance of ongoing clinical trials like SERENA-6 and VIKTORIA-1. Dr. Rugo also addresses the implications of recent studies on antibody-drug conjugates, offering essential clinical tips for treatment selection and toxicity management.

Drs. Hope Rugo and Kristin Rojas discuss advances in managing menopausal symptoms, fertility preservation, and bone health for women on endocrine therapy for breast cancer. They explore treatment options and emphasize the importance of education and choosing medications with favorable side effect profiles. The use of DHEA, estrogen therapy, and bisphosphonates for symptom management and prevention is also discussed.